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SObjective: At present, there is no consensus on the optimal strategy for follow-up care after curative resection
for lung cancer. We sought to understand the patterns of recurrence and second primary lung cancer, and their
mode of detection, after resection for early-stage non–small cell lung cancer in patients who were followed by
routine surveillance computed tomography scan.
Methods: We reviewed the outcomes of consecutive patients who underwent resection for early-stage non–
small cell lung cancer at Memorial Sloan-Kettering Cancer Center between 2004 and 2009.
Results: A total of 1294 consecutive patients with early-stage non–small cell lung cancer underwent resection.
The median length of follow-up was 35 months. Recurrence was diagnosed in 257 patients (20%), and second
primary lung cancer was diagnosed in 91 patients (7%). The majority of new primary cancers (85 [93%]) were
identified by scheduled routine computed tomography scan, as were a smaller majority of recurrences (157
[61%]). During the first 4 years after surgery, the risk of recurrence ranged from 6% to 10% per person-year
but decreased thereafter to 2%. Conversely, the risk of second primary lung cancer ranged from 3% to 6%
per person-year and did not diminish over time. Additional testing after false-positive surveillance computed
tomography scan results was performed for 329 patients (25%), but only 4 of these patients (0.3%) experienced
complications as a result of subsequent invasive diagnostic procedures.
Conclusions: Almost all second primary cancers and the majority of recurrences were detected by post-
therapeutic surveillance computed tomography scan. The risk of recurrence for early-stage non–small cell
lung cancer survivors persisted during the first 4 years after resection, and vigilance in surveillance should be
maintained. (J Thorac Cardiovasc Surg 2013;145:75-82)Lung cancer is an aggressive malignancy that remains the
leading cause of cancer-related death in the United States.1
Its poor prognosis has been attributed to late detection and
its high rate of relapse despite attempts at curative
treatment. Continued follow-up after completion of therapy
is crucial to monitor for complications, recurrences, and
second primary malignancies, and new disease would
ideally be detected as early as possible. Low-dose computed
tomography (CT) screening of high-risk patients recently
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However, the use of routine imaging for the surveillance
of lung cancer survivors has not been well defined. As
a result, surveillance guidelines and practices vary greatly
in imaging frequency and modality.3 The interpretation of
previous studies is limited by their small sample sizes and
by the heterogeneity of their surveillance methods. Al-
though some studies have suggested that surveillance CT
scan is effective at detecting early second primary lung
cancer,4 the data are less clear regarding detection of recur-
rence. Some studies report that routine surveillance fails to
identify most asymptomatic recurrences.5 With recent ad-
vances in both surgical and medical therapy for lung cancer,
and with the increasing use of CT imaging for screening, the
number of survivors of early-stage lung cancer will likely
increase.We sought to understand the patterns of recurrence
and metachronous lung cancer, and the mode of their detec-
tion, after resection of early-stage non–small cell lung
cancer (NSCLC) in patients who were followed by surveil-
lance CT scan. Our objective was to characterize the
patterns of recurrence and second primary lung cancers in
patients with resected early-stage NSCLC and to assess
the efficacy of a surveillance strategy using scheduled
interval chest CT imaging alone.ardiovascular Surgery c Volume 145, Number 1 75
Abbreviations and Acronyms
CT ¼ computed tomography
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
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SPATIENTS AND METHODS
Patient Cohort
A retrospective review of a prospectively maintained database was per-
formed for patients who were treated for lung cancer and followed at
Memorial Sloan-Kettering Cancer Center between January 2004 and De-
cember 2009. Individuals who underwent complete surgical resection for
early-stage (pathologic stage I-II) NSCLC were included. Staging was per-
formed in accordancewith the seventh edition of the AJCC Cancer Staging
Manual.6 Exclusion criteria were small cell and carcinoid pathology, neo-
adjuvant therapy, incomplete resection, and previously treated lung cancer.
Patients without follow-up information after the initial postoperative visit
were not included. Events and outcomes were abstracted from the medical
record. Event status (defined as the first diagnosis of either recurrence or
second primary cancer) was censored at the last thoracic clinic follow-
up. Vital status was confirmed using the Social Security Death Index.
Follow-up was conducted until October 2011. The study was approved
by the Memorial Sloan-Kettering Cancer Center institutional review board.Surveillance Protocol
In general, postoperative lung cancer surveillance was performed in ac-
cordance with National Comprehensive Cancer Network guidelines.7
During the first 2 years after surgery, each patient received a physical ex-
amination, interval history, and chest/upper-abdominal CT scan with or
without contrast, at least every 6 to 12 months. Bronchoscopy, serum
markers, and positron emission tomography (PET) were not used in routine
follow-up. Follow-up visits and surveillance CT scans were performed
yearly thereafter. Although all clinic appointments were conducted at our
institution, some imaging studies were performed at outside facilities. At
each follow-up visit, all new studies were reviewed by the clinician. Pa-
tients were followed by their thoracic surgeon or an oncologist, a radiation
oncologist, or a nurse practitioner trained in thoracic survivorship care.Recurrence and Second Primary Lung Cancer
The principal end point was the development of a recurrence or second
primary lung cancer. Data extracted included the type of recurrence (dis-
tant, regional, or local), the method of detection, and whether the event
was detected at a scheduled clinic visit as part of routine surveillance or
through an unscheduled visit outside of the follow-up protocol. Themanner
of detection—whether by scheduled CT scan, presentation of new symp-
toms, or other means—was defined as the modality that led to the initiation
of further workup and diagnosis of treatment failure. Local recurrence was
defined as any new lesion adjacent to a staple line, to the bronchial stump,
or in the residual lobe (in cases of sublobar resection). Regional recurrences
involved lymph node stations 1 to 14 or the ipsilateral lung. Distant metas-
tasis consisted of extrathoracic disease, metastasis to the contralateral lung,
pleural metastasis, pleural effusion, or pericardial effusion. Diagnosis of re-
currence was confirmed by biopsy in most cases or by further imaging (eg,
PET scan or brain magnetic resonance imaging) to support the clinical di-
agnosis and the decision to initiate treatment.
Second primary lung cancer was defined according to the criteria of
Martini andMelamed.8 A new, distinct pulmonary malignancy was consid-
ered a second primary cancer if it fulfilled any 1 of the following 3 criteria:
(1) histologic results different from those of the index tumor; (2) same his-
tologic results as the index tumor but diagnosed 2 years after the primary
tumor; or (3) same histologic results as the index tumor, diagnosed within76 The Journal of Thoracic and Cardiovascular Surge2 years of the primary tumor, but located in different lobes or segments,
with no positive intervening lymph nodes and no evidence of metastasis.
Statistical Analysis
The time to treatment failure was calculated from the date of surgery to
the date of diagnosis of the event, by use of the date of the pathologic diag-
nosis whenever possible. Survival was estimated using the Kaplan–Meier
method. Patients who did not experience new events were censored at the
time of the last clinic follow-up. Except for the first year, the rate of recur-
rence and the rate of second primary cancer were calculatedwithinmutually
exclusive 12-month intervals after surgery with curative intent. Each 12-
month rate was determined by dividing the number of events observed dur-
ing that interval by the corresponding total follow-up time. Patientswhodied
or were lost to follow-up within the first 3 months were excluded from the
study. The recurrence rate for the first year reflected the rate observed be-
tween postoperative months 3 and 12. All patients who were still at risk of
having the event at the beginning of the interval were included in the calcu-
lation. As a result, all rates are expressed as the number of events per 100
person-years. Survival was compared across groups by use of the nonpara-
metric log-rank test. All statistical tests were 2-sided. SAS version 9.3 (SAS
Institute, Inc, Cary, NC) was used to perform all statistical analyses.
RESULTS
Patient and Treatment Characteristics
Of the 1445 patients with early-stage lung cancer who
were resected during the study period, 27 died within 90
days after surgery and 140 had no follow-up information af-
ter the initial postoperative visit. Therefore, a total of 1294
subjects had sufficient data to be included in the study, rep-
resenting 90.3% of all patients with early-stage lung cancer
resected during the study period at our institution. The me-
dian length of follow-up among patients who did not expe-
rience recurrence or have second primary cancer was
35 months from the date of surgery (range, 4-92 months).
Nine percent of the patients were followed for less than
1 year, 18% were followed for 2 to 3 years, 54% were fol-
lowed for 3 to 5 years, and 20% were followed for more
than 5 years. Baseline characteristics are listed in Table 1.
The mean number of scheduled surveillance CT scans re-
ceived per patient was 1.9 for year 1 and 1.5 for year 2, de-
creasing to 1.0 for year 6 and 0.8 for year 7.
Survival after diagnosis of recurrences or second primary
tumors was significantly worse for patients with recurrences
than for patients with second primary tumors (P< .001);
3-year survival from the date of recurrence or metachronous
lung cancer was 24% for those with recurrences and 67%
for those with second primary tumors.
Recurrence
Recurrences developed in 1 in 5 patients (257 [20%]) dur-
ing the study period (Table 2). Of these patients, 67 (26%)
had locoregional disease alone; the remainder had only dis-
tant recurrences (112 [44%]) or both distant and locore-
gional disease (78 [30%]). The majority of recurrences
(157 [61%]) were detected by scheduled surveillance CT
scan. Most of the remaining recurrences (82 [32%]) were
detected outside of the routine follow-up protocol, mostry c January 2013
TABLE 1. Baseline and treatment characteristics of 1294 patients
with early-stage non–small cell lung cancer
Characteristic No. (%)
Female sex 752 (58)
Current or former smokers 1098 (85)
Cigarette pack-y (mean  SD) 39  34
FEV1 (L, mean  SD) 2  0.07
FEV1 (% predicted, mean  SD) 89  21
Age (y, mean  SD) 69  10
Stage
IA 760 (59)
IB 319 (25)
IIA 134 (10)
IIB 81 (6)
Procedure
Lobectomy 955 (74)
Wedge 188 (14)
Segmentectomy 111 (9)
Bilobectomy 22 (2)
Pneumonectomy 17 (1)
Adjuvant therapy
None 1092 (84)
Chemotherapy 192 (15)
Chemotherapy and radiation 1 (<1)
Radiation 1 (<1)
Unknown 8 (1)
Pathologic diagnosis
Adenocarcinoma 995 (77)
Squamous 222 (17)
Large cell 32 (2)
Other 45 (4)
FEV1, Forced expiratory volume in 1 second; SD, standard deviation.
TABLE 2. Characteristics of 257 patients with recurrence
Characteristic No. (%)
Recurrence location
Locoregional 143
Regional lymph nodes 69 (48)
Same side 62 (43)
Staple line 40 (28)
Distant 188
Pleural disease 67 (36)
Contralateral lung 44 (23)
Brain 36 (19)
Liver 22 (12)
Bone 17 (9)
Chest wall 15 (8)
Adrenal 15 (7)
Detection method
Surveillance CT 157 (61)
Symptoms 81 (32)
Other 17 (7)
Unknown 2 (1)
Treatment of recurrence
Chemotherapy 90 (35)
RT 37 (14)
ChemoþRT 30 (12)
SurgeryþRT 18 (7)
Surgery 13 (5)
Other 14 (5)
None 17 (7)
Unknown 38 (15)
CT, Computed tomography; RT, radiation therapy.
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The most common symptoms included neurologic changes,
bone pain, dyspnea, and hoarseness.When recurrences were
analyzed by the type of relapse, surveillance CT scan de-
tected 82% of locoregional-only recurrences (n ¼ 55). In
contrast, only 46% of distant-only recurrences (n ¼ 51)
were detected by surveillance CT scan. The majority of re-
currences (215 [85%]) were confirmed by biopsy. Approx-
imately half of the patients with relapses (120 [47%])
received systemic therapy with chemotherapy or chemora-
diation. In contrast, 26% of patients (n¼ 68) received local
therapy with radiation or surgery.
Approximately one third of recurrences (179 [71%]) were
diagnosedmore than 2 years after surgery. The hazard rate for
recurrence peaked during the second year (10 events per 100
person-years of follow-up) but remained elevated, at 7 and 6
events per 100 person-years duringyears 3 and 4, respectively
(Figure 1).Only at postoperativeyear 5 did the recurrence rate
decrease markedly, to 2 events per 100 person-years.Second Primary Lung Cancer
Second primary lung cancer was detected in 91 patients
(7%) (Table 3). Scheduled surveillance CT scan detectedThe Journal of Thoracic and Cthe majority of second primary lung cancers (85 [93%]).
Tissue confirmation of second primary malignancies was
obtained for 90 cases (99%). Most second primary malig-
nancies (77 [85%]) were in the same histologic category
as the index tumor (ie, adenocarcinoma or squamous) but
demonstrated different histologic patterns (eg, lepidic vs
micropapillary). Almost all were diagnosed as early-stage
cancers (stage I, 84 [92%]; stage II, 4 [4%]). Correspond-
ingly, more than half of these patients were subsequently
treated with surgery (55 [60%]). Wedge resection was the
most common procedure performed (46 [82%]). Unlike
that for recurrences, the hazard rate for second primary can-
cer did not diminish after surgery, but instead increased over
time, from 3 events per 100 person-years in year 2 to 6
events per 100 person-years in year 5 (Figure 1).
False-Positive Results From Surveillance Computed
Tomography Scans
In addition to the 157 patients who had recurrences de-
tected by surveillance CT scan, 329 asymptomatic patients
(25%) had abnormal or indeterminate surveillance CT scan
results and underwent additional testing that did not result
in a diagnosis of recurrence or second primary cancer.
The most common noninvasive test performed was repeat
short-interval CT scan within 2 to 3 months of the incidentardiovascular Surgery c Volume 145, Number 1 77
FIGURE 1. Hazard rates of recurrent and second primary lung cancer after resection over time.
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in 61 patients (5%). CT-guided needle biopsy was the most
frequent invasive procedure, performed in 41 patients (3%).
Among the 329 patients who received false-positiveTABLE 3. Characteristics of 91 patients with second primary lung
cancer
Characteristic No. (%)
Detection method
Surveillance CT 85 (93)
Symptoms 2 (2)
Other 2 (2)
Unknown 3 (3)
Stage of second primary
IA 73 (80)
IB 11 (12)
IIA 1 (1)
IIB 3 (3)
IIIA 3 (3)
Pathologic diagnosis
Adenocarcinoma 72 (79)
Squamous 13 (14)
Small cell 3 (3)
Large cell 2 (2)
Treatment
Surgery 51 (56)
RT 23 (25)
Chemotherapy 3 (3)
Other 9 (10)
None 1 (1)
Unknown 4 (4)
Resection
Wedge 46 (82)
Lobectomy 6 (11)
Segmentectomy 3 (5)
Pneumonectomy 1 (2)
CT, Computed tomography; RT, radiation therapy.
78 The Journal of Thoracic and Cardiovascular Surgesurveillance CT scan results, a total of 4 complications re-
sulted from subsequent invasive procedures, for a 0.3%
risk of complications resulting from ultimately unnecessary
invasive procedures (3 individuals developed pneumothora-
ces from CT-guided lung biopsies and required hospitaliza-
tion, and 1 patient experienced persistent air leak and
empyema after an open biopsy). No deaths resulted from
these complications. In addition, 14 nonlung malignancies,
either primary or metastatic, were diagnosed incidentally
during the course of routine CT surveillance.DISCUSSION
Weexamined the utility ofCT surveillance in the follow-up
care of 1294 resected early-stage lung cancer survivors and
characterized their patterns of recurrence and second primary
lung cancer. Although the majority of patients in this cohort
had stage I disease, we still observed new events in moreTABLE 4. Tests performed as a result of false-positive surveillance
computed tomography scan results
Modality No. (%)
Noninvasive
Short-interval CT scan 275 (21)
PET 70 (5)
US 8 (<1)
Bone scan 3 (<1)
Chest x-ray 1 (<1)
Invasive
CT-guided biopsy 41 (3)
Bronchoscopy/EBUS 16 (1)
Open biopsy 4 (<1)
Thoracentesis 4 (<1)
Mediastinoscopy 3 (<1)
CT, Computed tomography; PET, positron emission tomography; US, ultrasound;
EBUS, endobronchial ultrasound.
ry c January 2013
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Sthan one quarter of patients, with 20% developing recurrent
disease and another 7% developing second primary lung
cancer. Despite the conventional wisdom that recurrences
occur during the first 2 years after resection, we found that
a high risk of recurrence persisted for up to 4 years after resec-
tion. CT surveillance was successful in detecting more than
90% of the second primary cancers and approximately two
thirds of the recurrences diagnosed during the study period.
After the first year, metachronous lung cancers developed at
a rate of 3% to 6% per person-year, higher than the rate of
1% to 3% previously reported in other series. Indeterminate
or false-positive results led to additional testing in one quarter
of the patients. Five percent of all patients underwent invasive
procedures as the consequence of a false-positive surveillance
test result, but a major complication developed in only 0.3%
(4 patients). To our knowledge, this is the largest series to date
on recurrence and new primary lung cancer development in
patients followed by surveillance CT scan.
The detection rate of early-stage lung cancer has in-
creased with the increasing use of cross-sectional imaging,
such as CT scanning, in the diagnostic armamentarium of
health care providers. Advances in surgical technique and
minimally invasive technology have led to the widespread
adoption of video-assisted thoracoscopic approaches to ana-
tomic resection for the treatment of early-stage lung cancers.
The resulting confluence of these factors has led to a growing
contingent of patients undergoing surgery for early-stage
cancers and the recognition of the need to define better stan-
dards of care for lung cancer survivors. The National Lung
Screening Trial convincingly demonstrated that CT screen-
ing of high-risk patients significantly reduced lung cancer
mortality.2 One could argue that a patient with a recent his-
tory of lung cancer also could be considered to be at high
risk, raising the question of whether a similar utility of CT
screening would be observed among lung cancer survivors.
Although several organizations have recommended
various guidelines that include CT scanning for follow-up
after curative treatment for lung cancer, there is no
consensus, highlighting a lack of clarity on the issue.3,7
Furthermore, although most authors advocate some form
of imaging surveillance, others have previously suggested
a follow-up protocol based on symptoms alone, citing the
failure of routine surveillance imaging to detect recurrences
in asymptomatic patients.5 In a study by Pairolero and col-
leagues,9 patients treated for stage I NSCLC were closely
followed by history, physical examination, and chest
x-ray, as well as by blood, urine, and sputum studies. How-
ever, 41% of recurrences were still detected outside of
scheduled visits. Because 53% of recurrences were symp-
tomatic, the authors reported that symptoms, not scheduled
tests, were the most sensitive recurrence detection method.
The outcomes of CT surveillance have been reported in
several series.4,10,11 Chiu and colleagues10 reported that sur-
veillance standard-dose CT after curative resection wasThe Journal of Thoracic and Cmore sensitive than low-dose CT and chest x-ray. In a deci-
sion analysis by Kent and colleagues,12 the cost of surveil-
lance CT was estimated to be $47,676 per quality-adjusted
life-year gained. Age more than 65 years, cost of CT more
than $700, incidence of second primary lung cancer less
than 1.6% per person-year, and false-positive rate of
more than 14% made CT surveillance cost-ineffective.
In contrast, other authors have recommended more ag-
gressive surveillance programs that combine CT screening
with routine bronchoscopy.11 In one study of 192 subjects
treated for NSCLC, the authors reported that an intensive
surveillance program using routine bronchoscopy and tho-
racic/abdominal CT scan was feasible and that it detected
a significant number (38%) of recurrences in asymptomatic
patients.
Recurrence
Recurrences developed in 1 of 5 patients with early-stage
lung cancer in the present study and were detected by sur-
veillance CT scan in more than 60% of cases. However,
for approximately one third of patients, the development
of symptoms prompted the diagnosis of recurrence during
the interval between surveillance scans. The majority of
recurrences involved metastatic disease to distant sites
(Table 2) and were treated correspondingly, with systemic
therapy. Locoregional recurrences alone occurred in one
quarter of patients, including in the ipsilateral lung or re-
gional lymph nodes, which were potentially amenable to
local therapy. The risk of recurrence reached a plateau at
2 years but remained elevated for up to 4 years, before
declining. A recent analysis of the recurrence dynamics in
1506 patients with stage I to IIIA NSCLC who underwent
resection between 1995 and 2008 similarly demonstrated
elevated hazard rates of recurrence for up to 4 years after
surgery.10 Moreover, in a long-term follow-up of 285 pa-
tients after surgery for stage I NSCLC, Murthy and
colleagues13 used parametric modeling to develop a multi-
phase hazard model. They reported an early hazard phase in
the first 5 years after surgery, followed by a constant late
phase thereafter. However, in contrast to our analysis,
only tumors with different histology were considered meta-
chronous malignancies.
Second Primary Lung Cancer
Second primary cancers developed less frequently than
recurrences did. In a retrospective series by Lamont and col-
leagues,4 124 patients underwent surveillance chest x-rays
and CT scans. Up to 58% and 37% of second primary
tumors were detected by CT and chest x-ray, respectively.
Approximately 68% of patients benefited from surgical re-
section. In our study, CT surveillance was able to detect
more than 90% of second primaries. As expected, the
majority of these cancers were detected at an early stage,
and their treatment correspondingly centered on localardiovascular Surgery c Volume 145, Number 1 79
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Our observed rate of second primary cancers was higher
than the rate of 1% to 3% per patient-year reported in pre-
vious studies.14 The increased proportion of adenocarci-
noma relative to squamous cell histologic profile may
predispose our patient population to multifocal or second
primary cancers, compared with the populations in older
studies. The inclusion of patients with more advanced dis-
ease in other studies may have introduced the competing
risk of higher recurrence rates and lower survival, thereby
decreasing the observed number of second primary cancers.
Finally, studies in which routine surveillance CT scan was
not performed may have mistaken advanced second pri-
mary tumors as recurrences from the index tumors.8,15
Potential Risks of Computed Tomography
Surveillance
With any diagnostic test comes the risk of false-positive
results and their unintended consequences. False-positive
results often lead to further testing, which can involve inva-
sive procedures or increased exposure to radiation, while in-
creasing patient anxiety and costs. Postoperative changes in
the resected patient may complicate the interpretation of ra-
diographic abnormalities and lead to a higher incidence of
false-positive results. One quarter of the patients in our
cohort required additional workup—because of abnormali-
ties found on surveillance CT scans—that ultimately failed
to identify any evidence of recurrent malignancy or second
primary lung cancer. Only 5% of patients underwent what
could be considered unnecessary invasive procedures for
false-positive or indeterminate surveillance scan results;
CT-guided needle biopsy was themost common such proce-
dure. Of importance, only 0.3% of the patients in our cohort
experienced a complication unnecessarily for what was
ultimately a false-positive surveillance scan result. The
decision to act on a CT scan read as abnormal is highly
operator-dependent and relies on the clinical judgment of
the clinician. One study reported that only 29% of all sur-
veillance CT scans reported as abnormal by the radiologist
were actually considered suspicious enough by the clinician
to warrant additional testing.12 Korst and colleagues16 re-
ported that pleural effusion and pulmonary nodules greater
than 1 cm or an increase in size correlated with recurrence.
Defining our false-positive rate with respect to the clinical
context, rather than simply including all scans reported as
abnormal on the radiology report, affords a more accurate
estimate of the true risks of postoperative surveillance.
Implications for Surveillance
The use of routine surveillance CT imaging is important
in the follow-up care of early-stage lung cancer survivors.
The risk of second primary lung cancer remains high after
definitive resection. Surveillance CT scan detected more
than 90% of second primary lung cancers at an early stage,80 The Journal of Thoracic and Cardiovascular Surgewhen definitive local therapy was possible for most pa-
tients. Likewise, surveillance CT scan detected the majority
of new recurrences before the onset of symptoms. Several
randomized control trials have demonstrated a survival
benefit with chemotherapy, compared with supportive
care, in patients with advanced lung cancer.13 Given that
the observed rate of recurrence remained elevated during
the first 4 years after surgery, it may be beneficial to main-
tain close-interval follow-up throughout this period.
The concept of surveillance presumes that there is
a benefit from earlier detection. At present, no randomized
prospective study has been performed to evaluate the out-
comes of regimens with different surveillance intensities.
One meta-analysis of postoperative surveillance found
a trend toward improved survival among patients who
received intensive follow-up.14 However, the analysis in-
cluded studies with small sample sizes and different defini-
tions of intensive follow-up. The value of screening for
second primary cancers seems plausible in light of the
results of the National Lung Screening Trial, but it remains
less clear whether earlier detection of distant recurrences
can lead to improved survival or quality of life. Further un-
derstanding will depend on randomized, controlled trials to
assess survival and patient-centered outcomes. At present,
one such study is under way.12 The IFCT-0302 trial is
a phase III, multicentric, randomized, controlled trial that
aims to study the benefit of surveillance CT and fiberoptic
bronchoscopy after complete resection for stage I to IIIa
NSCLC. In addition to attending scheduled clinic visits, pa-
tients are randomized to receive chest x-ray or chest x-ray,
CT scan, and fiberoptic bronchoscopy. Chest CT scan is the
most commonly recommended surveillance test in most
guidelines. Nonetheless, the majority of recurrences in
this patient population are distant, and most are extrathora-
cic. PET-CT is now commonly used in preoperative staging
of lung cancer. In a small series, postresection surveillance
using PET-CT identified recurrences that were missed by
chest CT.17 However, PET-CT was less sensitive than CT
in the detection of small adenocarcinomas and ground-
glass lesions. At present, its role in surveillance after surgi-
cal resection remains to be defined. Another important
unexplored aspect of CT surveillance is the benefit of a reg-
imen tailored to patient characteristics, such as age, comor-
bidities, and extent of resection. An individualized
approach to follow-up should be evaluated in future studies.
Study Limitations
There are several limitations to the present study, includ-
ing those inherent in retrospective analyses. This was
a single-institution experience, albeit large, and it may not
be generalizable to other cohorts. The study cohort was lim-
ited to patients followed in our institution; those followed
elsewhere were not included. The patterns of recurrence
and second primary lung cancer can be affected byry c January 2013
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analyses were precluded by the lack of information on the
cause of death for all patients. Furthermore, the definition
of second primary lung cancer remains controversial. Al-
though the criteria of Martini and Melamed8 are the most
widely used, they may miscategorize some tumors, leading
to inaccuracies in rates of recurrence and second primary
lung cancer. However, it is still crucial to distinguish second
primary tumors from relapse in clinical practice because of
the significant differences in their treatment and prognosis.
Last, surveillance scans were performed at predefined inter-
vals. Recurrences may develop in between CT scans and
clinic appointments. Interval censoring may lead to an over-
estimation of time to event in our analysis.
CONCLUSIONS
Routine CT surveillance detected the majority of recur-
rences, as well as the majority of second primary lung
cancers. We found that the rate of recurrence remained ele-
vated until 4 years after surgery, which is in contrast to the
conventional wisdom. False-positive surveillance scan
results led to subsequent invasive procedures for only 5%
of patients. Most of the second primary lung cancers were
detected at early stages, and more than half of patients un-
derwent surgical resection. On the basis of our results, we
support the use of CT surveillance for survivors of early-
stage NSCLC. However, the optimal interval between sur-
veillance scans remains subject to further study.
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Dr Sean C. Grondin (Calgar, Alberta, Canada). This is an im-
portant article for thoracic surgeons. Many organizations are pub-
lishing guidelines on CT screening, as you mentioned, and it is
a hot topic for discussion. There are a lot of resources at stake,
so I appreciate your group trying to tackle this important question.
I have just a few questions for you. Many patients undergo CT
for follow-up of a nodule, but they are concerned about the radia-
tion exposure. I noticed in your protocol, the first 2 years you were
doing CT scans with contrast and then after that it was CT scans
without contrast. Can you explain to me the justification for using
contrast in the first 2 years? This approach contradicts other CT
screening guidelines by other organizations.
Dr Lou.You mean the justification for using contrast in the first
2 years?
Dr Grondin. Yes, most good CT radiologists will tell you that
you probably do not need contrast and that a CTwithout contrast is
good for screening, so why would you need contrast?
Dr Lou.We used CTwith contrast in the first 2 years because it
may be more effective in identification of hilar or mediastinal
lymph node metastases, as well as liver metastases. However, we
do recognize that the effectiveness of contrast versus noncontrast
CT has not been adequately evaluated in lung cancer surveillance.
In fact, the most recent National Comprehensive Cancer Network
recommendations were changed from CTwith contrast for the first
2 years to CT with or without contrast. The use of contrast in fol-
low-up essentially may make logical sense, but this has not been
validated by large prospective data.
Dr Grondin. Fair enough. I noticed your recurrence rate is
higher than what you would expect from historical series, 6% to
10%. Can you explain to me why that might be in your series?
Is this a reflection of the staging of the patients before they under-
went operation, they were not fully staged, or why is this higher in
your group do you think?
Dr Lou. I am not sure if the recurrence rate found in our group
was actually higher than in other series. The traditionally quoted
5-year recurrence rate of stage I disease is 20% to 39%. We found
that 20% of patients developed recurrences. But one thing we did
that was different was that in addition to looking at only the pro-
portion of recurrence over time, we looked at the rate of recur-
rence-meaning events over the number of months followed
within each 12-month interval, and that is the recurrence rate
we found.
Dr Grondin. The next question I have pertains to imaging of
patients for follow-up. If we all agree that CT is pretty good, and
down deep in my heart I think that CT probably is better than chestardiovascular Surgery c Volume 145, Number 1 81
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Sx-ray at following patients postoperatively, do you think that might
be even better than CT?
Dr Lou. Although PET scan has not been part of any of the or-
ganizations’ guidelines for surveillance, it recently has been inves-
tigated by some groups in Korea and the United States. The last
study that I found actually gave patients both CT scan and PET sur-
veillance, and they found that the PET scan was able to detect
a few percentages more of recurrences, most of which were distal.
However, when compared with CT scans, PET scans also missed
a few cases, especially when these masses are localized to the
lung if they were small or ground-glass opacities. So there are
pluses and minuses of PET scans, and I think more studies are war-
ranted in this area. But one must be cautious in interpreting these
studies, because the question of which is the superior modality
should be the actual effect on survival and patient-oriented out-
comes instead of only slight improvement in detection sensitivity.
Dr Grondin. My last question has to do with survival. That is
the elephant in the room. It is great to do imaging studies such
as CT, but at the end of the day is there any improvement in sur-
vival? I noticed that approximately three quarters of your patients
had distant metastases detected by CT. I am not aware of any data
that treating this subgroup of patients significantly extends sur-
vival. What are your thoughts on whether this early detection of re-
current disease with CT will translate into a survival advantage?
DrLou. This is something we thought of extensively as a group.
Again, there have been no prospective randomized trials looking at
the exact effect of earlier detection by surveillance programs.
However, at least for second lung primaries from our studies and
some previous series, you can see that most of them were able to
be detected in the early stage when curative therapies could be
given. It could be inferred that this kind of early detection would
lead to a survival benefit in those with a second primary tumor,
but again prospective verification is needed. However, it is more
controversial when you are talking about recurrences because
most patients with recurrences can only receive palliative therapy,
so the question of whether that kind of therapy would be more ben-
eficial if given a few months or weeks before would actually affect
long-term survival is more controversial and definitely needs to be
studied.We should not make a judgment on that before prospective
studies are done.
Dr Grondin. Thank you, and great job.82 The Journal of Thoracic and Cardiovascular SurgeDrRobert Shen (Rochester, Minn). I noted that 25% of patients
with a second primary lung cancer were treated with external beam
radiation therapy rather than surgical resection. Do you have
a sense of how many of those patients were medically ineligible
or thought to be medically ineligible for further surgery or were
offered surgery and refused? A corollary to that is what is your
institutional algorithm for a patient who is thought to have a second
primary? Is the patient offered surgery as the first treatment or is it
thought to be equivalent to offer stereotactic radiation?
Dr Lou. With regard to second primary lung cancers, it is al-
ways interesting to look at the outcomes and their treatments.
We do not have the exact numbers and the exact reasons why these
patients received surgery versus another treatment; however, I
would suspect a lot of these patients having undergone one surgical
resection already may have limited physiologic and respiratory re-
serve, which may limit their ability to undergo surgery, but that is
just a general sense of what I think happened. In terms of how the
decision was made exactly in each case, it was most likely depen-
dent on each radiologist and surgeon, but it is our institution’s prac-
tice that whenever a second primary lung cancer is detected, the
best alternative should be surgical resection if tolerated.
Dr Frederic Grannis (Duarte, Calif). This is the second of 2
important articles presented during this meeting on metachronous
lung cancer, and, although they are single institution reviews,
when those single institutions are Mayo Clinic and Memorial
Sloan Kettering, people have to pay close attention. I think yours
is the stronger study because it relies on a defined diagnostic reg-
imen, and I think the evidence is stronger, but I have a problem.
Your second author, Dr Peter Bach, authored an article in The
Journal of the American Medical Association last month in which
he published lung cancer screening guidelines for the American
College of Chest Physicians and American Society of Clinical
Oncology. In those guidelines he ignored his own data presented
today by omitting this important ultra-high risk group of people
from lung cancer screening guidelines. I think this will have
adverse consequences and that lives will be lost because of that
omission. So when you return to New York City, please ask
Dr Bach why he omitted his own data in writing the American
College of Chest Physicians and American Society of Clinical
Oncology guidelines.
Dr Lou. Thank you.ry c January 2013
